Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HC 7366

X
Drug Profile

HC 7366

Alternative Names: HC-7366

Latest Information Update: 28 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HiberCell
  • Class Antineoplastics; Small molecules
  • Mechanism of Action EIF2AK4 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Bladder cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 20 May 2024 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy) in USA (PO) (NCT06285890)
  • 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Renal cell carcinoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top